Compare Stocks: NRXP, DRUG, ASMB, and CTNM

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.61 -0.3%	$29.33	$21.80 ▼ $39.71	$480.70M	1.13	186,712 shs	117,453 shs
CTNM Contineum Therapeutics	$12.73 +1.4%	$15.08	$8.60 ▼ $17.78	$478.90M	0.75	349,528 shs	534,127 shs
DRUG Bright Minds Biosciences	$51.66 -0.3%	$71.29	$48.94 ▼ $123.75	$502.65M	-5.36	209,926 shs	91,877 shs
NRXP NRx Pharmaceuticals	$2.87 -4.0%	$3.45	$1.62 ▼ $5.05	$124.27M	2.19	1.08 million shs	731,343 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	-5.21%	-30.53%	-12.20%	-4.05%
CTNM Contineum Therapeutics	0.00%	-7.17%	-26.33%	-16.27%	+5.37%
DRUG Bright Minds Biosciences	0.00%	-15.05%	-28.86%	-25.12%	-1.75%
NRXP NRx Pharmaceuticals	0.00%	-9.94%	-15.77%	-25.25%	+1.36%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASMB Assembly Biosciences	$23.61 -0.3%	$29.33	$21.80 ▼ $39.71	$480.70M	1.13	186,712 shs	117,453 shs
CTNM Contineum Therapeutics	$12.73 +1.4%	$15.08	$8.60 ▼ $17.78	$478.90M	0.75	349,528 shs	534,127 shs
DRUG Bright Minds Biosciences	$51.66 -0.3%	$71.29	$48.94 ▼ $123.75	$502.65M	-5.36	209,926 shs	91,877 shs
NRXP NRx Pharmaceuticals	$2.87 -4.0%	$3.45	$1.62 ▼ $5.05	$124.27M	2.19	1.08 million shs	731,343 shs

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASMB Assembly Biosciences	0.00%	-5.21%	-30.53%	-12.20%	-4.05%
CTNM Contineum Therapeutics	0.00%	-7.17%	-26.33%	-16.27%	+5.37%
DRUG Bright Minds Biosciences	0.00%	-15.05%	-28.86%	-25.12%	-1.75%
NRXP NRx Pharmaceuticals	0.00%	-9.94%	-15.77%	-25.25%	+1.36%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASMB Assembly Biosciences	2.83	Moderate Buy	$47.50	102.34% Upside
CTNM Contineum Therapeutics	2.50	Moderate Buy	$21.00	59.82% Upside
DRUG Bright Minds Biosciences	2.78	Moderate Buy	$143.83	186.18% Upside
NRXP NRx Pharmaceuticals	2.43	Hold	$34.50	1,055.78% Upside

Current Analyst Ratings Breakdown

Latest NRXP, DRUG, ASMB, and CTNM Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/28/2026	CTNM Contineum Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Equal Weight	$18.00 ➝ $17.00
9/15/2026	CTNM Contineum Therapeutics	JonesTrading Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$26.00 ➝ $24.00
9/15/2026	CTNM Contineum Therapeutics	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$20.00 ➝ $19.00
9/15/2026	DRUG Bright Minds Biosciences	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
9/14/2026	NRXP NRx Pharmaceuticals	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$10.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$53.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
9/1/2026	ASMB Assembly Biosciences	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$52.00
9/1/2026	ASMB Assembly Biosciences	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$53.00 ➝ $45.00
8/26/2026	NRXP NRx Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/26/2026	NRXP NRx Pharmaceuticals	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Hold ➝ Strong Sell

(Data available from 9/28/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASMB Assembly Biosciences	$72.30M	6.61	N/A	N/A	$13.04 per share	1.80
CTNM Contineum Therapeutics	$50M	9.89	N/A	N/A	$6.99 per share	1.88
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	$8.33 per share	N/A
NRXP NRx Pharmaceuticals	$1.23M	105.08	N/A	N/A	($0.54) per share	-5.53

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASMB Assembly Biosciences	-$6.12M	$1.02	23.18	469.50	N/A	-0.06%	-0.02%	-0.02%	11/9/2026 (Estimated)
CTNM Contineum Therapeutics	-$59.98M	-$1.73	N/A	N/A	N/A	N/A	-24.73%	-23.51%	10/29/2026 (Estimated)
DRUG Bright Minds Biosciences	-$8.74M	-$2.08	N/A	N/A	N/A	N/A	-12.46%	-12.30%	N/A
NRXP NRx Pharmaceuticals	-$28.62M	-$0.55	N/A	N/A	N/A	-691.81%	N/A	-63.92%	11/13/2026 (Estimated)

Latest NRXP, DRUG, ASMB, and CTNM Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/17/2026	Q3 2026	DRUG Bright Minds Biosciences	-$1.2230	-$0.17	+$1.0530	-$0.17	N/A	N/A
8/14/2026	Q2 2026	NRXP NRx Pharmaceuticals	-$0.1067	-$0.44	-$0.3333	-$0.44	$1.33 million	$1.10 million
8/13/2026	Q2 2026	ASMB Assembly Biosciences	-$0.7242	-$0.20	+$0.5242	-$0.20	$8.60 million	$13.37 million
7/30/2026	Q2 2026	CTNM Contineum Therapeutics	-$0.4488	-$0.40	+$0.0488	-$0.40	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASMB Assembly Biosciences	N/A	N/A	N/A	N/A	N/A
CTNM Contineum Therapeutics	N/A	N/A	N/A	N/A	N/A
DRUG Bright Minds Biosciences	N/A	N/A	N/A	N/A	N/A
NRXP NRx Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASMB Assembly Biosciences	N/A	13.99	13.99
CTNM Contineum Therapeutics	N/A	37.17	37.17
DRUG Bright Minds Biosciences	N/A	122.00	122.00
NRXP NRx Pharmaceuticals	N/A	0.86	0.86

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASMB Assembly Biosciences	19.92%
CTNM Contineum Therapeutics	N/A
DRUG Bright Minds Biosciences	40.52%
NRXP NRx Pharmaceuticals	4.27%

Insider Ownership

Company	Insider Ownership
ASMB Assembly Biosciences	3.50%
CTNM Contineum Therapeutics	7.90%
DRUG Bright Minds Biosciences	42.66%
NRXP NRx Pharmaceuticals	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASMB Assembly Biosciences	73	20.36 million	19.65 million	Optionable
CTNM Contineum Therapeutics	51	37.62 million	34.65 million	N/A
DRUG Bright Minds Biosciences	25	9.73 million	5.58 million	Not Optionable
NRXP NRx Pharmaceuticals	29	43.30 million	40.53 million	Optionable

NRXP, DRUG, ASMB, and CTNM Headlines

Recent News About These Companies

Head to Head Contrast: BeOne Medicines (NASDAQ:ONC) and NRx Pharmaceuticals (NASDAQ:NRXP)

September 28 at 8:14 AM | americanbankingnews.com

Analyzing LENZ Therapeutics (NASDAQ:LENZ) & NRx Pharmaceuticals (NASDAQ:NRXP)

September 25 at 4:44 AM | americanbankingnews.com

NRx Pharmaceuticals Reports FDA Reclassifies Ketamine Amendment As Minor

September 16, 2026 | rttnews.com

NRx Pharmaceuticals Announces FDA Reclassification of ANDA Amendment for Preservative-Free Ketamine, Revises GDUFA Goal Date to November 10, 2026

September 15, 2026 | quiverquant.comQ

NRx Pharmaceuticals (Nasdaq: NRXP) Reports Update from the FDA Revising Previous Major Amendment to a Minor Amendment for Preservative-free Ketamine

September 15, 2026 | globenewswire.com

European Patent for ALS Program Expands the Story: HOPE Deploys Robotic TMS & FDA Commercialization Path Advances: NRx Pharmaceuticals: NAS DAQ: NRXP

September 14, 2026 | financialcontent.comF

NRx Pharmaceuticals' (NRXP) Buy Rating Reaffirmed at BTIG Research

September 14, 2026 | marketbeat.com

GeNeuro Secures European Patent For GNK-301 In ALS

September 14, 2026 | rttnews.com

NRx Pharmaceuticals: Promising Ketamine Opportunity In Psychiatry

September 14, 2026 | seekingalpha.com

GeNeuro Announces European Patent for GNK-301, an Anti-HERV K Antibody for ALS, and Plans for Phase I Trials

September 14, 2026 | quiverquant.comQ

GeNeuro, Inc., an NRx Company (Nasdaq:NRXP) is awarded European Patent Rights for GNK-301, a novel drug candidate to treat Amyotrophic Lateral Sclerosis (ALS)

September 14, 2026 | globenewswire.com

FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)

September 11, 2026 | financialcontent.comF

NRX Pharmaceuticals' HOPE Therapeutics to Deploy Zeta's TMS Robotic System

September 11, 2026 | finance.yahoo.com

NRx Pharmaceuticals, Inc.: NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

September 11, 2026 | finanznachrichten.de

NRx Pharmaceuticals (Nasdaq: NRXP) Subsidiary HOPE Therapeutics Begins Training and Deployment of Zeta Surgical's FDA-Cleared Robotic TMS System

September 11, 2026 | globenewswire.com

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Given Average Recommendation of "Hold" by Analysts

September 9, 2026 | marketbeat.com

NRx Pharmaceuticals to Participate in Upcoming Investor Conferences

September 8, 2026 | globenewswire.com

NRx targets 2026 KETAFREE approval and outlines SPARC-TMS trial in 400 patients backed by military funding

August 18, 2026 | seekingalpha.com

NRx Pharmaceuticals (Nasdaq:NRXP) Reports Second Quarter 2026 Financial Results and Provides Corporate Update; Conference Call to be Held on Monday, August 17th at 4:30pm ET

August 17, 2026 | globenewswire.com

NRx Pharmaceuticals, Inc. (NRXP) Reports Q2 Loss, Misses Revenue Estimates

August 14, 2026 | zacks.com

NRX Pharmaceuticals Inc Ordinary Shares NRXP

August 13, 2026 | morningstar.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

View All

NRXP, DRUG, ASMB, and CTNM Company Descriptions

Assembly Biosciences NASDAQ:ASMB

$23.61 -0.06 (-0.25%)

Closing price 04:00 PM Eastern

Extended Trading

$23.62 +0.00 (+0.02%)

As of 04:15 PM Eastern

Assembly Biosciences, Inc., a biotechnology company, develops therapeutic candidates for the treatment of viral diseases. It develops ABI-5366, a long-acting herpes simplex virus (HSV) helicase-primase inhibitor that is in Phase 1a/1b clinical trial to treat recurrent genital herpes; ABI-1179, which is in Phase 1a/1b clinical trial for the treatment of recurrent genital herpes; and ABI-6250, a small molecule orally bioavailable hepatitis delta virus entry inhibitor that is in Phase 1a clinical trial. The company also develops ABI-4334, a next-generation capsid assembly modulator, which is in Phase 1b clinical trial for the treatment of hepatitis B virus (HBV). In addition, it develops an oral non-nucleoside polymerase inhibitor targeting transplant-related herpesviruses; and a small molecule interferon-a receptor agonist targeting HBV and HDV. The company has collaboration agreements with Gilead Sciences, Inc. and BeiGene, Ltd. The company was formerly known as Ventrus Biosciences, Inc. and changed its name to Assembly Biosciences, Inc. in June 2014. Assembly Biosciences, Inc. was incorporated in 2005 and is headquartered in South San Francisco, California.

Contineum Therapeutics NASDAQ:CTNM

$12.73 +0.17 (+1.35%)

Closing price 04:00 PM Eastern

Extended Trading

$12.74 +0.00 (+0.04%)

As of 04:10 PM Eastern

Contineum Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on discovering and developing novel oral small molecule therapies for neuroscience, inflammation, and immunology indications with high unmet need. Its lead asset is PIPE-791, a novel, brain penetrant, small molecule inhibitor of the lysophosphatidic acid 1 receptor (LPA1R) for the treatment of idiopathic pulmonary fibrosis and progressive multiple sclerosis (MS). The company also develops PIPE-307, a novel, small molecule selective inhibitor of the muscarinic type 1 M1 receptor to treat depression and relapse remitting MS; and CTX-343, a peripherally-restricted LPA1R antagonist. Contineum Therapeutics, Inc. was formerly known as Pipeline Therapeutics, Inc. and changed its name to Contineum Therapeutics, Inc. in November 2023. The company was incorporated in 2009 and is headquartered in San Diego, California.

Bright Minds Biosciences NASDAQ:DRUG

$51.66 -0.14 (-0.27%)

Closing price 04:00 PM Eastern

Extended Trading

$51.69 +0.03 (+0.06%)

As of 05:15 PM Eastern

Bright Minds Biosciences Inc., a biotechnology company, develops therapeutics to improve the lives of patients with severe and life-altering diseases in the United States. Its portfolio of selective 5-HT receptor agonists includes 5-HT2C, 5-HT2A, and 5-HT2C/A for the treatment of epilepsy, pain, and neuropsychiatry; and BMB-101 which completes phase 1 trial for undisclosed seizure disorder. The company also developing BMB-202 for the treatment of depression, anxiety, and PTSD; and BMB-201 for the treatment of anxiety. It has collaboration with National Institutes of Health for the treatment of epilepsy; University of Texas Medical Branch to treat impulse control disorders, such as binge eating; and Medical College of Wisconsin. Bright Minds Biosciences Inc. was founded in 2017 and is headquartered in New York, New York.

NRx Pharmaceuticals NASDAQ:NRXP

$2.87 -0.12 (-4.01%)

Closing price 04:00 PM Eastern

Extended Trading

$2.93 +0.06 (+2.09%)

As of 06:15 PM Eastern

NRx Pharmaceuticals, Inc., a clinical-stage bio-pharmaceutical company, develops novel therapeutics for the treatment of central nervous system disorders, including suicidal depression, post-traumatic stress disorder, and chronic pain. Its products include NRX-101 (D-cycloserine/Lurasidone), an oral, fixed dosed combination of D-cycloserine and lurasidone that earned food and drug administration-designated breakthrough therapy for suicidal treatment-resistant bipolar depression; and NRX-100 (ketamine), which has been awarded FDA fast track designation for the treatment of severe bipolar depression with acute suicidal ideation and behavior. The company has a partnership with Alvogen Inc. and Lotus Pharmaceutical Company; development and manufacturing agreement with Nephron Pharmaceuticals, Inc. and Alcami; license agreement with Apkarian Technologies; development and license agreement with Glytech; license agreement with Sarah Herzog Memorial Hospital. The company was founded in 2015 and is based in Wilmington, Delaware.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRXP, DRUG, ASMB, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRXP, DRUG, ASMB, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRXP, DRUG, ASMB, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRXP, DRUG, ASMB, and CTNM Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Contineum Therapeutics NASDAQ:CTNM

Bright Minds Biosciences NASDAQ:DRUG

NRx Pharmaceuticals NASDAQ:NRXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest NRXP, DRUG, ASMB, and CTNM Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest NRXP, DRUG, ASMB, and CTNM Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

NRXP, DRUG, ASMB, and CTNM Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

Top Headlines

NRXP, DRUG, ASMB, and CTNM Company Descriptions

Assembly Biosciences NASDAQ:ASMB

Contineum Therapeutics NASDAQ:CTNM

Bright Minds Biosciences NASDAQ:DRUG

NRx Pharmaceuticals NASDAQ:NRXP

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools